Evidence map›Paper›PMID 40943059›Full record

ArticleInternational journal of molecular sciences2025

Fully Automated Measurement of GFAP in CSF Using the LUMIPULSE

Hisashi Nojima, Mai Yamamoto, Jo Kamada, Tomohiro Hamanaka, Katsumi Aoyagi

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hisashi NojimaFUJIREBIO INC., 1-8-1 Akasaka, Minato-ku, Tokyo 107-0052, Japan.ORCID 0000-0002-8907-5767
Mai YamamotoFUJIREBIO INC., 1-8-1 Akasaka, Minato-ku, Tokyo 107-0052, Japan.
Jo KamadaFUJIREBIO INC., 1-8-1 Akasaka, Minato-ku, Tokyo 107-0052, Japan.
Tomohiro HamanakaFUJIREBIO INC., 1-8-1 Akasaka, Minato-ku, Tokyo 107-0052, Japan.
Katsumi AoyagiFUJIREBIO INC., 1-8-1 Akasaka, Minato-ku, Tokyo 107-0052, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Glial fibrillary acidic protein (GFAP) has been shown to be a reliable biomarker for detecting neurological disorders. Recently, we developed the Lumipulse

Indexed as

Alzheimer DiseaseGlial Fibrillary Acidic ProteinAgedAged, 80 and overAmyloid beta-PeptidesBiomarkersCognitive DysfunctionFemaleHumansImmunoenzyme TechniquesMaleMiddle AgedPeptide FragmentsROC Curvetau ProteinsAmyloid beta-PeptidesBiomarkersGFAP protein, humanGlial Fibrillary Acidic ProteinPeptide Fragmentstau ProteinsAlzheimer’s diseaseCLEIAGFAP

Identifiers

PMID40943059
PMCPMC12428071

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.